Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Oramed Pharmaceuticals Inc. (ORMP) had Normalized Income after Taxes of $38.31M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$38.31M |
|
-- |
|
-- |
|
$3.66M |
|
$-3.66M |
|
$53.10M |
|
$49.44M |
|
$49.44M |
|
$38.31M |
|
$38.31M |
|
$38.31M |
|
|
Normalized Income after Taxes |
$38.31M |
$-3.66M |
|
$-3.63M |
|
40.77M |
|
41.97M |
|
$0.94 |
|
$0.91 |
|
| Balance Sheet Financials | |
$68.15M |
|
$0.56M |
|
$200.70M |
|
$268.85M |
|
$10.56M |
|
-- |
|
$20.01M |
|
$30.57M |
|
$238.28M |
|
$238.28M |
|
$238.28M |
|
40.93M |
|
| Cash Flow Statement Financials | |
$-2.92M |
|
$-19.49M |
|
$-10.36M |
|
$45.95M |
|
$13.20M |
|
$-32.74M |
|
$1.74M |
|
$-10.36M |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.45 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-2.92M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
16.08% |
|
16.08% |
|
14.25% |
|
16.08% |
|
$5.82 |
|
$-0.07 |
|
$-0.07 |
|